Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019

Ghulam Rehman Mohyuddin, Kelly Koehn, Leyla Shune, Muhammad Aziz, Al Ola Abdallah, Brian McClune, Siddhartha Ganguly, Joseph McGuirk, Suman Kambhampati

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Clinical trials may be inconsistent in their enrollment and reporting of patients with multiple myeloma (MM) who have renal insufficiency (RI). We performed a systematic review of all MM randomized clinical trials (RCT) from 2005–2019 to evaluate reporting of prevalence, eligibility criteria and outcomes of patients with RI and MM. One-hundred and twenty-three RCTs were included. Only 30% of studies clearly reported on the proportion of patients who had RI. Only 68.2% reported eligibility criteria pertaining to RI, with no uniformity in the reported criteria. The relative risk (RR) of disease progression or death in patients with RI was higher than those without, RR of 1.20 (1.003–1.431) for relapsed/refractory and 1.07 (1.001–1.046) for newly diagnosed. There is inconsistent reporting and enrollment of patients with RI on MM RCT’s. We advocate for higher enrollment of patients with RI and transparent reporting of their eligibility criteria and outcomes.

Original languageEnglish (US)
Pages (from-to)1386-1395
Number of pages10
JournalLeukemia and Lymphoma
Volume62
Issue number6
DOIs
StatePublished - 2021

Keywords

  • clinical trial
  • dialysis
  • Multiple myeloma
  • renal failure
  • renal insufficiency

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019'. Together they form a unique fingerprint.

Cite this